The MiningNewsWire Podcast

From the coronavirus pandemic to nationwide public unrest, 2020 has been a year that has inspired re-imagining public safety as the country has poignantly witnessed the challenges faced by law enforcement and security services across all verticals. The answers to some of society’s greatest problems today are not to be found simply in man power; rather, many of the answers lie in technology, like that of Knightscope Inc. (Profile), which is designed to augment and improve existing security infrastructure. Silicon Valley-based Knightscope, with its lineup of fully autonomous security robots, aligns with companies such as Palantir Technologies Inc. Class A (NYSE: PLTR), Axon Enterprise Inc. (NASDAQ: AAXN), L3Harris Technologies Inc. (NYSE: LHX) and Velodyne Lidar Inc. (NASDAQ: VLDR), which all share a passion for solving an array of security and safety problems, as well as protecting life and data with next-generation technology.

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application, which has been accepted for review, to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). The Company plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021, pending the FDA’s acceptance of the Company’s filing.

To view the original press release, visit https://nnw.fm/1Qib1

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application, which has been accepted for review, to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). The Company plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021, pending the FDA’s acceptance of the Company’s filing.

To view the original press release, visit https://nnw.fm/1Qib1

Investors are flocking to gold, silver and other precious metals in record numbers. One firm, BullionVault, reports that in the past six months demand to invest in gold, silver and platinum has reached almost half a billion dollars. “Net of client selling, investing in physical bullion on our peer-to-peer platform — first opened in 2005 — has now topped $442 million since the pandemic reached Europe and North America in March,” the company said. Mining companies around the world are benefitting from this rising investment tide, as they work to strengthen their positions, increase their holdings and ultimately provide more raw material for investors looking for more stable options. One of those companies, GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (GOH Profile), has secured options on some of the most promising properties in the highly productive Maricunga Gold Belt of Chile, including one yielding rock chip sample assays of 764 grams per tonne gold and 719 grams per tonne silver. GoldHaven plans to commence a drilling program in January 2021. Yamana Gold Inc. (NYSE: AUY) is expanding its footprint with its recent acquisition of Monarch properties in the Abitibi Region in Quebec, Canada. Other companies are releasing impressive reports regarding their current operations. Fosterville South Exploration Ltd (OTC: FSXLF) has provided high-grade assays of up to 152 grams per tonne gold in rock chip samples at the Star of the Glen target on the Golden Mountain project. Kinross Gold Corporation (NYSE: KGC) (TSX: K) announced the results of a prefeasibility study on its Lobo-Marte project, which indicates the potential of a cornerstone asset with attractive all-in sustaining costs to enhance the company’s long-term production profile. Gold Fields Limited American Depositary Shares (NYSE: GFI) is considering a number of automation projects at its South Deep gold mine in Gauteng, southwest of Johannesburg.

The surge in the price of gold has been well documented this year. The precious metal closed above $2,000 an ounce earlier this year, leading experts to forecast future prices from $2,300 (Goldman Sachs) to as high as $3,000 (Bank of America) in the coming months. In addition, copper prices have also risen to their highest levels in more than two years, climbing to more than $6,800 a ton. These numbers bode well for companies in the precious metals space, especially companies such as Josemaria Resources Inc. (TSX: JOSE) (OTCQB: JOSMF) (JOSE Profile), which has interests in both copper and gold. Earlier this month, JOSE released a feasibility study regarding its 100% owned Josemaria Copper-Gold Project in San Juan Province, Argentina. Other companies that are making moves in the base and precious metals sectors include Rio Tinto Plc (NYSE: RIO), which just announced that its Kennecott site in Utah is the first producer to be awarded the Copper Mark, the copper industry’s new independently assessed responsible production program. Freeport-McMoRan Inc. (NYSE: FCX) has commenced the Copper Mark process for six of its operating sites and has future plans to validate all of its operating sites against the program’s requirements. Southern Copper Corporation (NYSE: SCCO) recently released its Q3 2020 financial report, noting that its net sales totaled $2,129 million, up 14.5% compared to Q3 2019. Franco-Nevada Corporation (NYSE: FNV) also reported record revenue, EBITDA and net earnings in the third quarter with all material mining assets having returned to normal operations through the quarter.

The surge in the price of gold has been well documented this year. The precious metal closed above $2,000 an ounce earlier this year, leading experts to forecast future prices from $2,300 (Goldman Sachs) to as high as $3,000 (Bank of America) in the coming months. In addition, copper prices have also risen to their highest levels in more than two years, climbing to more than $6,800 a ton. These numbers bode well for companies in the precious metals space, especially companies such as Josemaria Resources Inc. (TSX: JOSE) (OTCQB: JOSMF) (JOSE Profile), which has interests in both copper and gold. Earlier this month, JOSE released a feasibility study regarding its 100% owned Josemaria Copper-Gold Project in San Juan Province, Argentina. Other companies that are making moves in the base and precious metals sectors include Rio Tinto Plc (NYSE: RIO), which just announced that its Kennecott site in Utah is the first producer to be awarded the Copper Mark, the copper industry’s new independently assessed responsible production program. Freeport-McMoRan Inc. (NYSE: FCX) has commenced the Copper Mark process for six of its operating sites and has future plans to validate all of its operating sites against the program’s requirements. Southern Copper Corporation (NYSE: SCCO) recently released its Q3 2020 financial report, noting that its net sales totaled $2,129 million, up 14.5% compared to Q3 2019. Franco-Nevada Corporation (NYSE: FNV) also reported record revenue, EBITDA and net earnings in the third quarter with all material mining assets having returned to normal operations through the quarter.

Investors are flocking to gold, silver and other precious metals in record numbers. One firm, BullionVault, reports that in the past six months demand to invest in gold, silver and platinum has reached almost half a billion dollars. “Net of client selling, investing in physical bullion on our peer-to-peer platform — first opened in 2005 — has now topped $442 million since the pandemic reached Europe and North America in March,” the company said. Mining companies around the world are benefitting from this rising investment tide, as they work to strengthen their positions, increase their holdings and ultimately provide more raw material for investors looking for more stable options. One of those companies, GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (GOH Profile), has secured options on some of the most promising properties in the highly productive Maricunga Gold Belt of Chile, including one yielding rock chip sample assays of 764 grams per tonne gold and 719 grams per tonne silver. GoldHaven plans to commence a drilling program in January 2021. Yamana Gold Inc. (NYSE: AUY) is expanding its footprint with its recent acquisition of Monarch properties in the Abitibi Region in Quebec, Canada. Other companies are releasing impressive reports regarding their current operations. Fosterville South Exploration Ltd (OTC: FSXLF) has provided high-grade assays of up to 152 grams per tonne gold in rock chip samples at the Star of the Glen target on the Golden Mountain project. Kinross Gold Corporation (NYSE: KGC) (TSX: K) announced the results of a prefeasibility study on its Lobo-Marte project, which indicates the potential of a cornerstone asset with attractive all-in sustaining costs to enhance the company’s long-term production profile. Gold Fields Limited American Depositary Shares (NYSE: GFI) is considering a number of automation projects at its South Deep gold mine in Gauteng, southwest of Johannesburg.

Big pharma and life science companies are making big news these days. The drug-development space is seeing strong investor interest as these companies make breakthrough advancements that address vast unmet medical needs. Strategic M&A moves are adding spice to the gumbo for investors as pioneering research remains focused on providing life-changing treatments for those suffering from a myriad of disorders. One of the largest and trickiest medical disorders of mankind may be on the cusp of more effective treatment. Depression is often kept in the dark and not talked about, but it is estimated that more than 17 million adults in the United States experienced at least one major depressive episode in 2019 alone, while one out of every four people in the world struggle with a diagnosable mental disorder. Life sciences company Cybin Inc. (Cybin Profile) is at the vanguard of new therapeutic protocols that target these disorders. Cybin is intent on developing psychedelic therapeutics along with unique delivery mechanisms that target depression as well as other psychiatric and neurological conditions. The company could benefit from two game-changing announcements made in the past few days: the company just completed its previously announced reverse takeover and a groundbreaking study published in JAMA Psychiatry reports that in a recent study a treatment featuring psilocybin actually worked better than typical antidepressant medications. Other drug-development companies are experiencing similar milestone moments. Last month Praxis Precision Medicines Inc. (NASDAQ: PRAX) closed on its upsized initial public offering of 11,500,000 shares of common stock, resulting in aggregate gross proceeds to Praxis of $218.5 million. Earlier this year, AbbVie Inc. (NYSE: ABBV) completed a transformative acquisition of Allergan. Less than a year ago, Axsome Therapeutics (NASDAQ: AXSM) realized more than $200 million when it closed on its public offering. And this summer Relmada Therapeutics Inc. (NASDAQ: RLMD) uplisted to trade on the Nasdaq Global Select Market.

Big pharma and life science companies are making big news these days. The drug-development space is seeing strong investor interest as these companies make breakthrough advancements that address vast unmet medical needs. Strategic M&A moves are adding spice to the gumbo for investors as pioneering research remains focused on providing life-changing treatments for those suffering from a myriad of disorders. One of the largest and trickiest medical disorders of mankind may be on the cusp of more effective treatment. Depression is often kept in the dark and not talked about, but it is estimated that more than 17 million adults in the United States experienced at least one major depressive episode in 2019 alone, while one out of every four people in the world struggle with a diagnosable mental disorder. Life sciences company Cybin Inc. (Cybin Profile) is at the vanguard of new therapeutic protocols that target these disorders. Cybin is intent on developing psychedelic therapeutics along with unique delivery mechanisms that target depression as well as other psychiatric and neurological conditions. The company could benefit from two game-changing announcements made in the past few days: the company just completed its previously announced reverse takeover and a groundbreaking study published in JAMA Psychiatry reports that in a recent study a treatment featuring psilocybin actually worked better than typical antidepressant medications. Other drug-development companies are experiencing similar milestone moments. Last month Praxis Precision Medicines Inc. (NASDAQ: PRAX) closed on its upsized initial public offering of 11,500,000 shares of common stock, resulting in aggregate gross proceeds to Praxis of $218.5 million. Earlier this year, AbbVie Inc. (NYSE: ABBV) completed a transformative acquisition of Allergan. Less than a year ago, Axsome Therapeutics (NASDAQ: AXSM) realized more than $200 million when it closed on its public offering. And this summer Relmada Therapeutics Inc. (NASDAQ: RLMD) uplisted to trade on the Nasdaq Global Select Market.

Pharmaceutical companies invest enormous amounts of time and money on the research and development of new drugs, typically years in the making and costing millions of dollars. Only occasionally is a new drug developed that’s approved and generates more than $1 billion per year in sales, a benchmark in the industry commonly called a “blockbuster.” Blockbusters are scarce, but the proverbial quest for blockbuster drugs continues unabated because of vast unmet medical needs and because blockbuster therapeutics can be worth tens of billions of dollars during their patent-protected lives. Little wonder that pharmaceutical giants often buy up promising new drugs, some even in their infancy, not just to fill their pipeline or mesh with current R&D projects but also to bank on a bonanza of prospective revenues that could exceed $100 billion. With so much at stake, it only makes sense to pay special attention to scientists who have previously developed and delivered these blockbusters. With this in mind, expectations are high for 180 Life Sciences Corp. (180 Profile) since the founders have significant expertise in developing new therapeutics that were sold to big pharma for billions. They are renowned for development of some of the largest-selling drugs to ever come to market. Now they aim to do it again with a pipeline of drug candidates in sequential stages of development that address large untapped markets. The founding scientists at 180 Life Sciences discovered the anti-TNF drug class that led to Remicade, the fourth all-time best-selling drug in the world.